FDA Peptide Drug Master File Guidance 2026: Updated Expectations for Type II DMF Submissions and CMC Documentation

Background: The Role of Type II DMFs in Peptide Drug Development

A Drug Master File (DMF) is a confidential FDA submission by which a manufacturer (typically a peptide API manufacturer or CDMO) provides detailed information about a drug substance, drug product component, or manufacturing facility to support one or more NDA, ANDA, BLA, or IND applications, without disclosing proprietary manufacturing information directly to the pharmaceutical company filing the application.

Type II DMFs specifically cover Drug Substances, Drug Substance Intermediates, and Material Used in the Preparation of Drug Substances. For peptide APIs, the Type II DMF is the primary confidential repository for:

• Complete synthetic route and process description
• Raw material specifications and control strategy
• In-process controls and acceptance criteria
• Drug substance specifications and analytical methods
• Stability data package
• Container-closure system information

DMFs are not approved per se, they are referenced by pharmaceutical applications (INDs, NDAs, ANDAs) and FDA reviews the DMF content in the context of the referencing application's review. A deficient DMF can block FDA review of an NDA or ANDA that references it.

What FDA's Updated Guidance Clarifies

Analytical Characterization Expectations

FDA's 2023 draft guidance on analytical procedures for peptide drug substances established expectations for structural elucidation and extended characterization. The new DMF-specific guidance confirms that these expectations apply to the DMF submission context:

Primary structure determination: The DMF must include complete primary structure confirmation by at least two orthogonal methods. For peptides up to approximately 50 amino acids, this typically means:

• Amino acid analysis or Edman degradation sequencing for sequence confirmation
• High-resolution mass spectrometry (HRMS) with precursor ion mass and fragmentation data (MS/MS for sequence confirmation)
• Nuclear magnetic resonance (NMR) for select structural elements (particularly non-standard amino acid modifications, unusual linkages)

Post-translational and chemical modifications: Any intended modifications (PEGylation, fatty acid conjugation, disulfide bonds, amidation, cyclization) must be fully characterized with appropriate methods. Partial modification levels must be quantified and controlled.

Impurity characterization: FDA clarifies that impurity qualification thresholds consistent with ICH Q3A apply to peptide DMF submissions, but that process-related impurities specific to peptide synthesis (deletion sequences, truncated peptides, racemization products, oxidized variants) require additional characterization beyond what ICH Q3A contemplates for small molecules.

Process Control and in-Process Testing

The guidance addresses a common DMF deficiency: insufficient description and justification for in-process controls during SPPS.

Resin loading and coupling efficiency: FDA expects coupling efficiency monitoring during synthesis, with acceptance criteria justified by impact on final product quality. The guidance does not mandate specific methods but expects the DMF to describe the manufacturer's approach.

Cleavage and deprotection control: The guidance explicitly notes that incomplete deprotection (residual protecting groups) is a peptide-specific impurity risk that should be addressed in the process description and control strategy.

Purification controls: Preparative HPLC purification parameters (column type, gradient, load, cycle time) must be described. The guidance notes that purification strategy changes (column substitutions, gradient modifications) made after DMF submission require DMF updates, a compliance area where FDA has noted recurring deficiencies at inspections.

Reference Standard Requirements

Reference standard qualification in peptide DMFs has been inconsistently addressed historically. The updated guidance establishes:

Primary reference standard: Must be fully characterized by at least two independent orthogonal methods. The characterization package must demonstrate identity, purity, assigned content (with uncertainty), and stability. For commercial programs, FDA recommends maintaining the primary reference standard lot with sufficient quantity for the full commercial lifecycle or until a documented secondary lot transfer is completed.

Working reference standard qualification: When working reference standards (less tightly characterized, used for routine release testing) are used in addition to a primary standard, the qualification process (parallel analysis against primary) must be documented in the DMF.

Reference standard updates: If the primary reference standard lot is exhausted and a new lot is established, the DMF must be updated to reflect the new lot qualification data. FDA notes this is an area where CDMOs have been cited for lacking timely DMF updates.

Electronic DMF Requirements

FDA's electronic submission requirements now mandate eDMF format for all new Type II DMF submissions. Key requirements:

• Submissions must conform to FDA's Electronic Submissions Gateway (ESG) technical specifications
• Module 3 content must follow CTD format (M3.2.S for Drug Substance)
• Electronic signatures where required under 21 CFR Part 11
• Complete submission manifest and hyperlinked navigation

CDMOs and API manufacturers with legacy paper DMFs should review the status of their submissions. While FDA has not set a mandatory conversion deadline for all existing paper DMFs, CDMOs supporting active NDA/ANDA reviews may receive FDA reviewer requests to convert to eDMF format. Proactive conversion is advisable for any DMF supporting active drug applications.

Letter of Authorization Practices

When an NDA or ANDA applicant references a peptide DMF, they must obtain a Letter of Authorization (LOA) from the DMF holder. The LOA authorizes FDA to reference the DMF in review of the applicant's submission.

The updated guidance clarifies LOA scope and limitation:

LOA does not transfer compliance responsibility: A common misunderstanding is that an LOA transfers some QA responsibility to the DMF holder. The guidance explicitly states that the NDA/ANDA applicant retains full regulatory responsibility for the drug substance CMC, even when relying on a DMF for detailed manufacturing information.

Multiple applicant LOAs: A single DMF may be referenced by multiple applicant LOAs (multiple pharmaceutical companies can reference the same CDMO's DMF). This does not create privacy concerns between applicants, FDA maintains confidentiality of each applicant's submission separately.

LOA scope specificity: LOAs should specify the drug substance, manufacturing site, and process version being authorized. If a CDMO updates manufacturing processes (new synthesis route, facility change), applicants whose LOAs reference the prior process may need to update their LOAs and potentially supplement their applications to reference the updated DMF content.

Common DMF Deficiency Patterns and How to Avoid Them

FDA's guidance includes reference to common deficiency types identified in CDER reviews:

Deficiency: Incomplete impurity characterization Description: Impurities listed in specifications without identification (unknown impurities above the identification threshold) Resolution: Complete impurity identification using orthogonal methods (LC-MS for molecular weight, MS/MS for structural fragments); create an impurity library with retention times, masses, and structures; update specifications to reflect identified impurities

Deficiency: Stability data gaps Description: Stability data package missing required storage condition (accelerated, long-term, or intermediate temperature) Resolution: Conduct complete ICH Q1A stability studies per peptide storage conditions (often 2-8°C for lyophilized; 2-8°C or frozen for liquid API); ensure container-closure system for stability studies matches commercial packaging; include at minimum 6 months accelerated and 12 months long-term data for NDA submission

Deficiency: Manufacturing process inadequately described for audit trail Description: Process description insufficient for FDA inspection verification, FDA inspector cannot confirm manufacturing steps from DMF description Resolution: Process description must be detailed enough that a qualified reviewer could trace actual manufacturing steps against the description; include batch record format in DMF Annex

Deficiency: Reference standard lot expired or quantity insufficient Description: Primary reference standard exhausted without replacement lot qualified and DMF updated Resolution: Proactive reference standard lot planning, estimate consumption based on batch release testing frequency, hold reserves, and initiate next lot qualification before current lot is depleted

Practical Implications for CDMOs and Pharmaceutical Companies

For CDMOs: Regular DMF review and update programs are necessary compliance infrastructure. Designate a DMF responsible person with defined duties for update tracking, LOA management, and FDA correspondence. Budget for eDMF conversion if holding legacy paper submissions.

For pharmaceutical companies referencing DMFs: Due diligence on CDMO DMF status should be part of CDMO qualification. Key questions: When was the DMF last updated? What open deficiencies or FDA correspondence exists? Is the manufacturing process version in the DMF current? What is the reference standard lot status and projected availability?

For regulatory teams: Understanding the DMF/NDA interface, specifically, how DMF deficiencies can delay NDA/ANDA review, is critical for realistic CMC submission timelines. Build in buffers for DMF remediation when referencing DMFs from CDMOs with pending deficiency letters.

People Also Ask

What is a Type II DMF for peptide APIs?

A Type II Drug Master File (DMF) is a confidential FDA submission by a peptide API manufacturer (often a CDMO) that contains detailed manufacturing, analytical, and quality information about a peptide drug substance. It allows multiple pharmaceutical companies to reference the same manufacturing information in their drug applications (NDA, ANDA, IND) without requiring the manufacturer to disclose proprietary process details to the applicant. FDA reviews the DMF content in the context of each referencing application's review.

Do CDMOs need to update their DMFs when they change processes?

Yes, any significant manufacturing process change (new synthesis route, facility change, supplier change for critical starting materials, analytical method modification) generally requires a DMF amendment or annual report, depending on the change type. FDA guidance on post-approval changes (for commercial products) and the Q3A/Q3B guidelines for impurities provide the framework for classifying change types. Failure to update the DMF after changes creates regulatory risk, an FDA inspection finding that actual practices don't match DMF descriptions can result in observations or restrictions on applicant approvals.

How long does FDA take to review a peptide Drug Master File?

FDA does not formally "approve" DMFs, there is no review timeline commitment for DMF submissions alone. FDA reviews DMF content when a referencing application triggers the review. At that point, review timelines depend on the application type and priority: PDUFA commitments apply to NDA/BLA reviews (10 months standard review, 6 months priority review) and include DMF review within that timeline. ANDA reviews (generics) have separate performance goal timelines.